Business Wire

CA-PHELPS-BRAND

24.2.2021 14:02:12 CET | Business Wire | Press release

Share
Phelps Brand Launches Penny Oleksiak Collection

Phelps Brand, a global swim brand offering best-in-class, innovative swim products, today announced the launch of a collection inspired by World Champion swimmer Penny Oleksiak. The new collection features special design elements that embody the Phelps Brand global ambassador’s character and personality.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210224005085/en/

“I love being a part of the Phelps Brand team and I jumped at the chance to help create new designs around the products I’m already using,” said Oleksiak. “I want swimmers to feel good and look good while they’re training for their goals.”

The new collection is influenced by Penny’s personality and dedication to increasing participation in the sport, infusing pops of color and unique graphics to invoke feelings of fun and playfulness. The exclusive Penny Oleksiak collection begins to roll out this month with two products available to consumers worldwide so far. The initial product offering includes Xceed goggles that feature unique pink titanium lenses specially designed for training and racing as well as a Sakura swimsuit decorated with delicate Japanese cherry blossoms, known as a symbol for new beginnings.

“This special line was created to capture Penny’s fun, youthful spirit,” said Jessica Fitzsimon, Global Brand Director for Phelps Brand and Aqua Sphere. “We’re excited to redefine our top-of-the-line products with new designs that continue to celebrate the sport of swimming.”

Oleksiak was added to the Phelps Brand roster of global ambassadors in 2020. As part of the Phelps Team, Oleksiak trains and competes utilizing the industry-leading range of products from training equipment to performance swimsuits. A four-time Olympic medalist and six-time World Championship medalist, Oleksiak is a force on Team Canada. As Canada’s youngest Olympic gold medalist, she holds the nation’s record for most Olympic medals at a single summer Games. In her short career she has become known for her exciting come from behind victories, winning four Olympic and six World medals. She currently holds the Olympic Record for the 100 Freestyle.

Made in Italy with Aqua Sphere technology, Phelps Brand develops a technologically advanced range of products from training equipment to performance swimsuits for competitive swimmers under the direction of Michael Phelps and Hall of Fame coach Bob Bowman.

To learn more or to purchase products, go to www.michaelphelps.com .

About PHELPS BRAND

The Phelps Brand offers best-in-class, innovative swim products that are inclusive and accessible to a broad range of swimmers across the competitive swimming lifecycle. Combining Aqua Sphere’s global product design expertise and distribution with Michael Phelps’ and Coach Bob Bowman’s experiences at the highest levels of swim performance, the Phelps Brand features technical swim products leveraging proprietary technologies and performance enhancing designs. For more information or to purchase Phelps Brand products, visit www.michaelphelps.com .

Link:

ClickThru

Social Media:

https://www.facebook.com/PhelpsSwimming

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye